Denali Therapeutics Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $330.5M | $105.1M | $48.7M |
| Operating income | -$555.3M | -$487.3M | -$196.7M | -$340.7M | -$295.8M |
| Operating expenses | $555.3M | $501.9M | $527.2M | $449.2M | $344.4M |
| Cash from operations | -$412.6M | -$347.7M | -$358.0M | -$244.7M | -$211.4M |
| Capital expenditure | $9.5M | $15.9M | $12.9M | $17.8M | $8.5M |
| Free cash flow | -$422.1M | -$363.6M | -$370.9M | -$262.5M | -$219.9M |
| Total assets | $1.1B | $1.4B | $1.2B | $1.5B | $1.4B |
| Total liabilities | $131.1M | $144.5M | $123.0M | $417.8M | $441.9M |
Shares outstanding 158.7M · Free float 89.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.